FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2743201835> ?p ?o ?g. }

• W2743201835 endingPage "9617" @default.
• W2743201835 startingPage "9608" @default.
• W2743201835 abstract "While gemcitabine has been the mainstay therapy for advanced pancreatic cancer, newer combination regimens (e.g. FOLFIRINOX) have extended patient survival, though carry greater toxicity. Biomarkers are needed to better stratify patients for appropriate therapy. Previously, we reported that one-third of pancreatic cancers harbor deletions or deleterious mutations in key subunits of the SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeling complex. The SWI/SNF complex mobilizes nucleosomes on DNA, and plays a key role in modulating DNA transcription and repair. Thus, we hypothesized that pancreatic cancers with SWI/SNF aberrations might exhibit compromised DNA repair, and show increased sensitivity to DNA damaging agents. Here, we studied human pancreatic cancer cell lines with deficient (or else exogenously reconstituted) SWI/SNF subunits, as well as normal pancreatic epithelial cells following SWI/SNF subunit knockdown. Cells were challenged with DNA damaging agents, including those used in current combination regimens, and then cell viability assayed. We found that pancreatic cells with SWI/SNF dysfunction showed markedly increased sensitivity to DNA damaging agents, and in particular DNA crosslinking agents (cisplatin and oxaliplatin). Assaying clearance of γH2AX confirmed that SWI/SNF dysfunction impaired DNA damage response/repair. Finally, by analyzing pancreatic cancer patient data from The Cancer Genome Atlas, we found that pancreatic cancers with SWI/SNF deficiency (subunit mutation and/or decreased expression) were associated with extended patient survival specifically when treated with platinum containing regimens. Thus, SWI/SNF dysfunction sensitizes pancreatic cancer cells to DNA crosslinking agents, and SWI/SNF mutation status may provide a useful biomarker to predict which patients are likely to benefit from platinum-containing chemotherapy regimens." @default.
• W2743201835 created "2017-08-17" @default.
• W2743201835 creator A5004031300 @default.
• W2743201835 creator A5008864107 @default.
• W2743201835 creator A5008936074 @default.
• W2743201835 creator A5027448540 @default.
• W2743201835 date "2017-08-08" @default.
• W2743201835 modified "2023-10-08" @default.
• W2743201835 title "SWI/SNF aberrations sensitize pancreatic cancer cells to DNA crosslinking agents" @default.
• W2743201835 cites W1523531555 @default.
• W2743201835 cites W1544851750 @default.
• W2743201835 cites W1931508686 @default.
• W2743201835 cites W1944188907 @default.
• W2743201835 cites W1976385056 @default.
• W2743201835 cites W2011422070 @default.
• W2743201835 cites W2016991737 @default.
• W2743201835 cites W2019299732 @default.
• W2743201835 cites W2021120490 @default.
• W2743201835 cites W2022093187 @default.
• W2743201835 cites W2030873172 @default.
• W2743201835 cites W2034852369 @default.
• W2743201835 cites W2040730809 @default.
• W2743201835 cites W2047664934 @default.
• W2743201835 cites W2050540286 @default.
• W2743201835 cites W2063851753 @default.
• W2743201835 cites W2067826589 @default.
• W2743201835 cites W2087436342 @default.
• W2743201835 cites W2098387013 @default.
• W2743201835 cites W2106578635 @default.
• W2743201835 cites W2112728955 @default.
• W2743201835 cites W2119079421 @default.
• W2743201835 cites W2126675803 @default.
• W2743201835 cites W2132310381 @default.
• W2743201835 cites W2144603423 @default.
• W2743201835 cites W2147966104 @default.
• W2743201835 cites W2151253787 @default.
• W2743201835 cites W2161884651 @default.
• W2743201835 cites W2164286021 @default.
• W2743201835 cites W2174602966 @default.
• W2743201835 cites W2320983896 @default.
• W2743201835 cites W2465641214 @default.
• W2743201835 cites W2474317928 @default.
• W2743201835 cites W2597062310 @default.
• W2743201835 cites W4210955308 @default.
• W2743201835 doi "https://doi.org/10.18632/oncotarget.20033" @default.
• W2743201835 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5839388" @default.
• W2743201835 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29515757" @default.
• W2743201835 hasPublicationYear "2017" @default.
• W2743201835 type Work @default.
• W2743201835 sameAs 2743201835 @default.
• W2743201835 citedByCount "9" @default.
• W2743201835 countsByYear W27432018352018 @default.
• W2743201835 countsByYear W27432018352019 @default.
• W2743201835 countsByYear W27432018352020 @default.
• W2743201835 countsByYear W27432018352021 @default.
• W2743201835 countsByYear W27432018352022 @default.
• W2743201835 countsByYear W27432018352023 @default.
• W2743201835 crossrefType "journal-article" @default.
• W2743201835 hasAuthorship W2743201835A5004031300 @default.
• W2743201835 hasAuthorship W2743201835A5008864107 @default.
• W2743201835 hasAuthorship W2743201835A5008936074 @default.
• W2743201835 hasAuthorship W2743201835A5027448540 @default.
• W2743201835 hasBestOaLocation W27432018351 @default.
• W2743201835 hasConcept C121608353 @default.
• W2743201835 hasConcept C126322002 @default.
• W2743201835 hasConcept C134935766 @default.
• W2743201835 hasConcept C143425029 @default.
• W2743201835 hasConcept C166941617 @default.
• W2743201835 hasConcept C167227067 @default.
• W2743201835 hasConcept C2776694085 @default.
• W2743201835 hasConcept C2778239845 @default.
• W2743201835 hasConcept C2780210213 @default.
• W2743201835 hasConcept C502942594 @default.
• W2743201835 hasConcept C54355233 @default.
• W2743201835 hasConcept C552990157 @default.
• W2743201835 hasConcept C71924100 @default.
• W2743201835 hasConcept C83640560 @default.
• W2743201835 hasConcept C86803240 @default.
• W2743201835 hasConceptScore W2743201835C121608353 @default.
• W2743201835 hasConceptScore W2743201835C126322002 @default.
• W2743201835 hasConceptScore W2743201835C134935766 @default.
• W2743201835 hasConceptScore W2743201835C143425029 @default.
• W2743201835 hasConceptScore W2743201835C166941617 @default.
• W2743201835 hasConceptScore W2743201835C167227067 @default.
• W2743201835 hasConceptScore W2743201835C2776694085 @default.
• W2743201835 hasConceptScore W2743201835C2778239845 @default.
• W2743201835 hasConceptScore W2743201835C2780210213 @default.
• W2743201835 hasConceptScore W2743201835C502942594 @default.
• W2743201835 hasConceptScore W2743201835C54355233 @default.
• W2743201835 hasConceptScore W2743201835C552990157 @default.
• W2743201835 hasConceptScore W2743201835C71924100 @default.
• W2743201835 hasConceptScore W2743201835C83640560 @default.
• W2743201835 hasConceptScore W2743201835C86803240 @default.
• W2743201835 hasIssue "11" @default.
• W2743201835 hasLocation W27432018351 @default.
• W2743201835 hasLocation W27432018352 @default.
• W2743201835 hasLocation W27432018353 @default.
• W2743201835 hasLocation W27432018354 @default.

• next